Document is current

Documents that mention this clinical trial

Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis
https://doi.org/10.34067/kid.0005852020

Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
https://doi.org/10.2215/cjn.11220720

Transforming the Care of Patients with Diabetic Kidney Disease
https://doi.org/10.2215/cjn.18641120

Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture
https://doi.org/10.2337/dbi19-0038

GLP-1 Receptor Agonists in Diabetic Kidney Disease
https://doi.org/10.2215/cjn.18771220

The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease
https://doi.org/10.2215/cjn.00020122

Management of type 2 diabetes in chronic kidney disease
https://doi.org/10.1136/bmjdrc-2021-002300

Obesity in CKD
https://doi.org/10.2215/cjn.09150822

Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
https://doi.org/10.2215/cjn.02690320

Documents that mention this clinical trial

▼Finerenone for CKD associated with type 2 diabetes
https://doi.org/10.1136/dtb.2023.000017

Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease
https://doi.org/10.2215/cjn.16201020

Effect of Losartan and Spironolactone on Triglyceride-Rich Lipoproteins in Diabetic Nephropathy
https://doi.org/10.1136/jim-2016-000102

Finerenone
https://doi.org/10.2337/cd21-0050

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
https://doi.org/10.1161/circulationaha.121.057983

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
https://doi.org/10.2215/cjn.06870520

Management of type 2 diabetes in chronic kidney disease
https://doi.org/10.1136/bmjdrc-2021-002300